Financings in Brief: Urohealth Systems:
This article was originally published in The Gray Sheet
Urohealth Systems: Firm's public offering of 2.5 mil. shares is priced at $8 per share. Urohealth filed a registration statement for the offering in October ("The Gray Sheet" Oct. 7, p. 18). Underwriters led by Bear Stearns, Piper Jaffray and Needham & Company hold an over-allotment option to buy 375,000 additional shares. Separately, Urohealth annouces Nov. 22 that its shares will commerce trading on the NASDAQ market on Nov. 26. Urohealth stock previously traded on the American Stock Exchange...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.